The process of reviewing and implementing the improved formulation led to a minor extension to the manufacturing process timeframe. Importantly, at this stage, there is only expected to be a small impact on the overall trial schedule. The Investigational New Drug application submission is now expected to be filed in December 2022, with the trial opening in January 2023.
